Introducing Elixir
Founded in 2002, Elixir Securities ("Elixir") is a London-based corporate finance boutique specializing in the global life sciences sectors, including pharmaceuticals, healthcare/research services, biotechnology, diagnostics, med tech and biofuels.
Elixir is focused on developing solutions for companies seeking to develop and execute their growth strategies either in part or entirely in Europe.
Our capabilities are aligned with the sector-specific financial challenges which these companies face. As scientists, first and foremost, we draw on a wealth of experience to provide our clients with solutions which not only reflect the demands of the financial markets, but also our understanding of the realities of the life sciences world.
"Primary markets" capabilities include public and private placements, PIPEs, secondary offerings, IPOs, pre-IPOs, buyouts/ins and special-situation deal structures, such as those which pre-fund corporate "buy-and-build" acquisition strategies. Elixir is also able to undertake mergers/acquisitions and product licensing mandates.
Securities which are available to companies may include term debt, fixed premium converts, variable priced converts, equity lines of credit and equity.
Elixir also helps smaller companies to identify and develop their key strategic messages and to prepare professional prospectuses (for product licensing purposes); private placement memorandums and marketing presentations.
Elixir News
Wound Solutions Closes First Tranche of Series A Investment
LONDON, February 2, 2009 - - Wound Solutions, today announced that it had reached a first closing of £2 m of its current £8 million Series A funding round. The first tranche of investment enables the company to reach a planned interim review of its current clinical study. Wound Solutions is developing electrotherapy devices for the treatment of chronic wounds. with its first product the VS01 focused on venous leg ulcers, the most prevalent form of chronic wound in the Western world....
MorEx Development Partners, LLP Closes £3.4m Private Placement
LONDON, November 3, 2008. Elixir Securities is pleased to announce that it has closed a £3.4m financing between newly-formed MorEx Development Partners, LLP ("MDP") and an investor group led by Stephens Investments. MDP will be focused on the clinical development of a novel new radiosensitiser, MorEx....
CeNeS Pharmaceuticals Placing To Raise £6.1M
CAMBRIDGE, July 27, 2007. CeNeS is pleased to announce that it proposes to raise approximately £6.1 million (before expenses) by means of a placing ("the Placing") of 5,789,137 new ordinary shares (the "Placing Shares") of 30 pence each ("New Ordinary Shares") at 105 pence per share....
Elixir Voted Highest Ranking Biotech 'Independent' In The European Thomson Extel Survey
LONDON, June 8, 2005. Elixir Securities, a London-based equity research company specialising in the global pharmaceutical and biotech sectors was the highest ranking 'Independent' Broker in the 2005 European Thomson Extel survey....
Read more news relating to Elixir »
Pre-D Reports
The current economic conditions have added to already challenging times in the UK life sciences sectors.
The scarcity of early stage capital which is available for investment, is well recognised. However, at a time when more companies than ever are looking for transactions, we are also seeing a contraction in the number of specialist investors, advisors and infrastructure.
PreD reports are intended to fill this growing gap in expertise for the benefit of Corporates, Advisors and Investors.
Click here for PreD reports»
Biofuels
Elixir has recently developed its capabilities in the biofuels space.
Click here for more»
Call Back
If you would like to talk to Elixir about a specific project, please click on the button below. The most appropriate person will then contact you directly, to discuss your specific needs.
